Hereditary and Early onset breast cancer: Comprehensive personalized Assessment, early Risk Evaluation, and clinical management

HORIZON.1.2HORIZON-TMA-MSCA-DNID: 101227105
EC Contribution
€46,975
Consortium Size
33 orgs
β–ΆSummary

Breast cancer is the most frequently diagnosed cancer in women, with European countries having some of the highest age-standardized incident rates of early-onset (< age 50) breast cancer in the world. Yet, our understanding of the genetic and environmental factors triggering the pathophysiology of the disease in young women is still limited. Advancing breast cancer prevention and treatment demands a holistic approach towards an accurate and early tumour detection – strongly linked with better clinical outcomes. HER-CARE aims to revolutionize the approach to hereditary and early-onset breast cancer through an innovative, interdisciplinary research and training program. The project will address critical gaps in early detection, risk stratification, and clinical management by developing tools that integrate genetic, molecular, and imaging data with state-of-the-art technologies, including artificial intelligence, machine learning, and advanced statistical modelling. These efforts will uncover: i) new molecular mechanisms and biological targets that can be targeted in hereditary and early-onset breast cancer; ii) better multifactorial risk profiles to enhance prediction accuracy; iii) new minimally invasive tools and assays to detect and intercept breast cancer early. The resulting tools and methodologies will: enhance early detection with accessible, personalized treatment and preventative strategies tailored to young women; ii) improve genetic counselling and clinical management; iii) improve treatment guidelines/ cancer prevention programs; and iv) reduce the high rate of misdiagnoses and overtreatment.HER-CARE will train the next generation of researchers by equipping 15 Doctoral Candidates with multidisciplinary skills spanning genetics, bioinformatics, molecular biology, cancer epidemiology, biostatistics, and computational science to transform the management of hereditary and early-onset breast cancer.

Consortium (33)

πŸ‡³πŸ‡± STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUISNL
coordinator
πŸ‡³πŸ‡± ACADEMISCH ZIEKENHUIS LEIDENNL
partner
πŸ‡¬πŸ‡§ ASTRAZENECA UK LIMITEDGB
partner
πŸ‡ͺπŸ‡Έ CONSORCIO PARA LA EXPLOTACION DEL CENTRO NACIONAL DE ANALISIS GENOMICOES
partner
πŸ‡³πŸ‡± EVIDENCIO BVNL
partner
πŸ‡¬πŸ‡§ FOUNDATION FOR GENOMICS & POPULATION HEALTHGB
partner
πŸ‡ΊπŸ‡Έ iCAD, IncUS
partner
πŸ‡«πŸ‡· INSTITUT GUSTAVE ROUSSYFR
partner
πŸ‡¬πŸ‡§ INSTITUTE OF CANCER RESEARCH: THE ROYAL CANCER HOSPITAL LBGGB
partner
πŸ‡ΊπŸ‡Έ JOHNS HOPKINS UNIVERSITYUS
partner
πŸ‡ΈπŸ‡ͺ KAROLINSKA INSTITUTETSE
partner
πŸ‡©πŸ‡ͺ KLINIKUM DER UNIVERSITAET ZU KOELNDE
partner
πŸ‡¨πŸ‡Ύ KYPRIAKO IDRYMA EREVNON GIA TI MYIKI DISTROFIACY
partner
πŸ‡¨πŸ‡Ώ MASARYKOVA UNIVERZITACZ
partner
πŸ‡¦πŸ‡Ή MEDIZINISCHE UNIVERSITAET WIENAT
partner
πŸ‡³πŸ‡± Methylomics B.V.NL
partner
πŸ‡¬πŸ‡§ OXFORD NANOPORE TECHNOLOGIES LTDGB
partner
πŸ‡¬πŸ‡§ PROTEOTYPE DIAGNOSTICS LTDGB
partner
πŸ‡¦πŸ‡Ί QIMR Berghofer Medical Research InstituteAU
partner
πŸ‡©πŸ‡° REGION SYDDANMARKDK
partner
πŸ‡©πŸ‡ͺ SIEMENS HEALTHINEERS AGDE
partner
πŸ‡¨πŸ‡­ Sophia Genetics SACH
partner
πŸ‡³πŸ‡± STICHTING KONINGIN WILHELMINA FONDS VOOR DE NEDERLANDSE KANKERBESTRIJDINGNL
partner
πŸ‡³πŸ‡± STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUMNL
partner
πŸ‡¨πŸ‡Ύ STREMBLE VENTURES LTDCY
partner
πŸ‡©πŸ‡° SYDDANSK UNIVERSITETDK
partner
πŸ‡¬πŸ‡§ THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGEGB
partner
πŸ‡¬πŸ‡§ THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORDGB
partner
πŸ‡ͺπŸ‡Έ UNIVERSITAT DE BARCELONAES
partner
πŸ‡«πŸ‡· UNIVERSITE PARIS-SACLAYFR
partner
πŸ‡³πŸ‡± UNIVERSITEIT TWENTENL
partner
πŸ‡³πŸ‡± UNIVERSITEIT UTRECHTNL
partner
πŸ‡ΊπŸ‡Έ Veracyte, Inc.US
partner